Aptar Awarded Federal Government Contract to Advance Novel Sterilization Technology for Medical Devices
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241022369874/en/
Figure 1: ActivShield™ film ready to be placed in chamber for sterilization (chamber not required) (Graphic: Business Wire)
ActivShield™ technology leverages Aptar CSP Technologies’ 20+ years of material science expertise and is built upon the company’s proven 3-Phase Activ-Polymer™ platform, a highly engineered active material science solution trusted by global brands to protect sensitive drug products, medical devices, drug delivery systems and probiotics.
ActivShield™ technology is a portable, novel sterilization modality that does not require conventional infrastructure, power, or extensive training, and more importantly, does not present the health risk associated with the use of Ethelyne Oxide (EtO). ActivShield™ uses a highly engineered Activ-Film™ material that emits a controlled amount of chlorine dioxide gas to sterilize a wide range of medical devices and instruments.
“As an innovation leader in pharma dosing, dispensing and protection technologies, we are proud to work with the
Aptar’s technology can be custom engineered to meet the needs of specific devices and conditions. Its stability throughout shelf life and compact size (Figure 1) makes it easy to stockpile, and all materials are manufactured in
ActivShield™ technology is well-positioned to fill unmet sterilization needs in remote or emergency response civilian settings, which could significantly reduce infection risks stemming from inadequately sterilized medical devices and instruments. Additionally, the technology could reduce reliance on expensive and unsafe sterilization techniques such as EtO, which has come under recent scrutiny by the
For the military, ActivShield™ can help wounded service members, particularly those in far-forward environments, have access to sterilized instruments during critical pre-hospitalization periods, following severe injuries.
The five-year contract is valued at approximately
* This work is supported by the
About Aptar
Aptar is a global leader in drug and consumer product dosing, dispensing and protection technologies. Aptar serves a number of attractive end markets including pharmaceutical, beauty, food, beverage, personal care and home care. Aptar CSP Technologies leverages its active material science expertise to transform ideas into market opportunities, accelerate and de-risk the product development process, and provide complete solutions that improve consumers’ and patients’ lives. The company offers a complete set of services from concept ideation, to design and engineering, to product development, global production, quality control, and regulatory support that results in expedited speed-to-market. For more information, please visit www.csptechnologies.com and www.aptar.com.
This press release contains forward-looking statements, including the potential outcomes and the value of the contract for the development of the ActivShield™ technology. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts and by use of words such as “expects,” “anticipates,” “believes,” “estimates,” “future,” “potential,” “continues” and other similar expressions or future or conditional verbs such as “will,” “should,” “would” and “could” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: the successful integration of acquisitions; the regulatory environment; and competition, including technological advances. For additional information on these and other risks and uncertainties, please see our filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20241022369874/en/
Aptar Investor Relations Contact:
mary.skafidas@aptar.com
+1 347 351 6407
Aptar CSP Technologies Media Contact:
tricia.dozier@aptar.com
315-521-4555
Aptar Media Contact:
katie.reardon@aptar.com
+1 815 479 5671
Source: